Citations (75)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Peirong Liu, Pengyi Li, Qingyang Li, Hongzhu Yan, Xiaowei Shi, Chunliang Liu, Yu Zhang & Sheng Peng. (2021) Effect of Pretreatment of S-Ketamine On Postoperative Depression for Breast Cancer Patients. Journal of Investigative Surgery 34:8, pages 883-888.
Read now
Read now
Weiyun Chen, Shaohui Chen & Yuguang Huang. (2021) Induction and maintenance of procedural sedation in adults: focus on remimazolam injection. Expert Review of Clinical Pharmacology 14:4, pages 411-426.
Read now
Read now
Joanna Kryst, Paweł Kawalec & Andrzej Pilc. (2020) Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder. Expert Opinion on Pharmacotherapy 21:1, pages 9-20.
Read now
Read now
Fernanda S Correia-Melo, Felipe C Argolo, Lucas Araújo-de-Freitas, Gustavo Carneiro Leal, Flávio Kapczinski, Acioly Luiz Lacerda & Lucas C Quarantini. (2017) Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart review. Neuropsychiatric Disease and Treatment 13, pages 1627-1632.
Read now
Read now
Matthew D. Cooper, Joshua D. Rosenblat, Danielle S. Cha, Yena Lee, Ron Kakar & Roger S. McIntyre. (2017) Strategies to mitigate dissociative and psychotomimetic effects of ketamine in the treatment of major depressive episodes: a narrative review. The World Journal of Biological Psychiatry 18:6, pages 410-423.
Read now
Read now
Eric J. Lenze, Nuri B. Farber, Evan Kharasch, Julie Schweiger, Michael Yingling, John Olney & John W. Newcomer. (2016) Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial. The World Journal of Biological Psychiatry 17:3, pages 230-238.
Read now
Read now
Bartłomiej Pochwat, Agnieszka Pałucha-Poniewiera, Bernadeta Szewczyk, Andrzej Pilc & Gabriel Nowak. (2014) NMDA antagonists under investigation for the treatment of major depressive disorder. Expert Opinion on Investigational Drugs 23:9, pages 1181-1192.
Read now
Read now
Articles from other publishers (68)
Qiuwen Li, Kai Gao, Siqi Yang, Shuting Yang, Shouyu Xu, Yunfei Feng, Zhihong Bai, Anqi Ping, Shichao Luo, Lishan Li, Liangfeng Wang, Guoxun Shi, Kaiming Duan & Saiying Wang. (2023) Predicting efficacy of sub-anesthetic ketamine/esketamine i.v. dose during course of cesarean section for PPD prevention, utilizing traditional logistic regression and machine learning models. Journal of Affective Disorders 339, pages 264-270.
Crossref
Crossref
Liang Zhou & Jingjing Duan. (2023)
The role of
NMDARs
in the anesthetic and antidepressant effects of ketamine
. CNS Neuroscience & Therapeutics.
Crossref
Crossref
Tiantian Liu, Xinxin Zhang, Ao Li, Tingting Liu, Xue Yang, Huanhuan Zhang, Yanling Lei, Qianzi Yang & Hailong Dong. (2023) Effects of intra-operative administration of subanesthetic s-ketamine on emergence from sevoflurane anesthesia: a randomized double-blind placebo-controlled study. BMC Anesthesiology 23:1.
Crossref
Crossref
Ilaria D’Acquarica & Israel Agranat. (2023) The Quest for Secondary Pharmaceuticals: Drug Repurposing/Chiral-Switches Combination Strategy. ACS Pharmacology & Translational Science 6:2, pages 201-219.
Crossref
Crossref
Sheikh Shoib, Madhulika Kotra, Sana Javed, Vinh-Son Nguyen & Barikar C. Malathesh. (2022) Esketamine–A quick-acting novel antidepressant without the disadvantages of ketamine. Hormone Molecular Biology and Clinical Investigation 43:4, pages 505-511.
Crossref
Crossref
Aksharra Balachandran, Vanessa K. Tassone, Fathima Adamsahib, Anne-Marie Di Passa, Sarah Kuburi, Ilya Demchenko, Karim S. Ladha & Venkat Bhat. (2022) Efficacy of ketamine for comorbid depression and acute or chronic pain: A systematic review. Frontiers in Pain Research 3.
Crossref
Crossref
Caitlyn J. Bartsch & Jacob C. Nordman. (2022) Promises and Pitfalls of NMDA Receptor Antagonists in Treating Violent Aggression. Frontiers in Behavioral Neuroscience 16.
Crossref
Crossref
Fan Zhang, Jun Ding, Man Luo, Hao‐Hua Luo, Xiao‐Lin Sun, Xu Fang, Lei Chen, Jun Tao & Zhao‐Qiong Zhu. (2022) Effects of subanesthesia dose S‐ketamine induction on postoperative psychiatric complications after gynecological surgery. Ibrain 8:2, pages 165-175.
Crossref
Crossref
Sanne Y Smith-Apeldoorn, Maurice Vischjager, Jolien KE Veraart, Jeanine Kamphuis, Marije aan het Rot & Robert A Schoevers. (2022) The antidepressant effect and safety of non-intranasal esketamine: A systematic review. Journal of Psychopharmacology 36:5, pages 531-544.
Crossref
Crossref
Jacob C. Nordman, Caitlyn J. Bartsch & Zheng Li. (2022) Opposing effects of NMDA receptor antagonists on early life stress‐induced aggression in mice. Aggressive Behavior 48:3, pages 365-373.
Crossref
Crossref
Neethu K Nandan, Puneet K Soni, Ajay Parsaik & Aqeel Hashmi. (2022) “Esketamine” in Borderline Personality Disorder: A Look Beyond Suicidality. Cureus.
Crossref
Crossref
Grigorios N. Karakatsoulis & Konstantinos N. Fountoulakis. 2022. Glutamate and Neuropsychiatric Disorders. Glutamate and Neuropsychiatric Disorders
261
282
.
Weimin XuPeng WangDalong WangKe LiuShuaishuai ZhangWei ZhaoGuoqing Liu. (2021) S-ketamine alleviates carbon tetrachloride-induced hepatic injury and oxidative stress by targeting the Nrf2/HO-1 signaling pathway. Canadian Journal of Physiology and Pharmacology 99:12, pages 1308-1315.
Crossref
Crossref
Frederik Andreas Madsen, Trine Hjorslev Andreasen, Jane Lindschou, Christian Gluud & Kirsten Møller. (2021) Ketamine for critically ill patients with severe acute brain injury: Protocol for a systematic review with meta-analysis and Trial Sequential Analysis of randomised clinical trials. PLOS ONE 16:11, pages e0259899.
Crossref
Crossref
Bonnie Robinson, Qiang Gu & Jyotshna Kanungo. (2021) Antidepressant Actions of Ketamine: Potential Role of L-Type Calcium Channels. Chemical Research in Toxicology 34:5, pages 1198-1207.
Crossref
Crossref
Ezio Carboni, Anna R. Carta, Elena Carboni & Antonello Novelli. (2021) Repurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success?. Frontiers in Neuroscience 15.
Crossref
Crossref
Jack Brodeur, Ryley Mancine, Alyse Ley & Jed Magen. (2020) Does Peritraumatic Ketamine Reduce Symptoms of Post-Traumatic Stress Disorder?. Spartan Medical Research Journal 5:2.
Crossref
Crossref
Michele Protti, Roberto Mandrioli, Camilla Marasca, Andrea Cavalli, Alessandro Serretti & Laura Mercolini. (2020) New‐generation, non‐SSRI antidepressants: Drug‐drug interactions and therapeutic drug monitoring. Part 2: NaSSAs, NRIs, SNDRIs, MASSAs, NDRIs, and others. Medicinal Research Reviews 40:5, pages 1794-1832.
Crossref
Crossref
Fernanda S. Correia-Melo, Gustavo C. Leal, Flávia Vieira, Ana Paula Jesus-Nunes, Rodrigo P. Mello, Guilherme Magnavita, Ana Teresa Caliman-Fontes, Mariana V.F. Echegaray, Igor D. Bandeira, Samantha S. Silva, Diogo E. Cavalcanti, Lucas Araújo-de-Freitas, Luciana M. Sarin, Marco A. Tuena, Carolina Nakahira, Aline S. Sampaio, José A. Del-Porto, Gustavo Turecki, Colleen Loo, Acioly L.T. Lacerda & Lucas C. Quarantini. (2020) Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study. Journal of Affective Disorders 264, pages 527-534.
Crossref
Crossref
Adam Włodarczyk & Wiesław Jerzy Cubała. (2020) Safety and Tolerability of Ketamine Use in Treatment-Resistant Bipolar Depression Patients with Regard to Central Nervous System Symptomatology: Literature Review and Analysis. Medicina 56:2, pages 67.
Crossref
Crossref
Lijia Chang, Yan Wei & Kenji Hashimoto. 2020. Ketamine. Ketamine
105
125
.
Sanne Y. Smith-Apeldoorn, Jolien K. E. Veraart, Jeanine Kamphuis, Antoinette D. I. van Asselt, Daan J. Touw, Marije aan het Rot & Robert A. Schoevers. (2019) Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial. BMC Psychiatry 19:1.
Crossref
Crossref
Cheng-yi Chen & Xiaowei Lu. (2019)
Enantioselective Syntheses of (
S
)-Ketamine and (
S
)-Norketamine
. Organic Letters 21:16, pages 6575-6578.
Crossref
Crossref
Agnieszka Pałucha-Poniewiera. (2018) The role of glutamatergic modulation in the mechanism of action of ketamine, a prototype rapid-acting antidepressant drug. Pharmacological Reports 70:5, pages 837-846.
Crossref
Crossref
Fernanda S. Correia-Melo, Gustavo C. Leal, Michelle S. Carvalho, Ana Paula Jesus-Nunes, Carolina B.N. Ferreira, Flávia Vieira, Guilherme Magnavita, Lucas A.S. Vale, Rodrigo P. Mello, Carolina Nakahira, Felipe C. Argolo, Tanise Cardoso, Cezar D.S. Souza, Ana Teresa C. Fontes, Marcelo B. Ferreira, Lucas Araújo-de-Freitas, Marco A. Tuena, Mariana V.F. Echegaray, Diogo E. Cavalcanti, Ana C. Lucchese, Igor D. Bandeira, Manuela Telles, Cássio S. Lima, Aline S. Sampaio, Samantha S. Silva, Roberta F. Marback, José A. Del-Porto, José Neander Abreu, Luciana M. Sarin, Camilla S. Paixão, Lucas P. Carvalho, Paulo R.L. Machado, Gustavo Turecki, Acioly L.T. Lacerda & Lucas C. Quarantini. (2018) Comparative study of esketamine and racemic ketamine in treatment-resistant depression. Medicine 97:38, pages e12414.
Crossref
Crossref
F. Caraci, F. Calabrese, R. Molteni, L. Bartova, M. Dold, G. M. Leggio, C. Fabbri, J. Mendlewicz, G. Racagni, S. Kasper, M. A. Riva & F. Drago. (2018) International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-resistant Depression: From Antidepressant Classifications to Novel Pharmacological Targets. Pharmacological Reviews 70:3, pages 475-504.
Crossref
Crossref
Subhi Marwari & Gavin S Dawe. (2018) (R)-fluoxetine enhances cognitive flexibility and hippocampal cell proliferation in mice. Journal of Psychopharmacology 32:4, pages 441-457.
Crossref
Crossref
F. Artigas, P. Celada & A. Bortolozzi. (2018) Can we increase the speed and efficacy of antidepressant treatments? Part II. Glutamatergic and RNA interference strategies. European Neuropsychopharmacology 28:4, pages 457-482.
Crossref
Crossref
Brooke Short, Joanna Fong, Veronica Galvez, William Shelker & Colleen K Loo. (2018) Side-effects associated with ketamine use in depression: a systematic review. The Lancet Psychiatry 5:1, pages 65-78.
Crossref
Crossref
Gianluca Serafini, Shawn Hayley, Mehdi Ghasemi & Mario Amore. 2017. Neuroprotective Natural Products. Neuroprotective Natural Products
293
311
.
Kenichi Fukumoto, Hidetoh Toki, Michihiko Iijima, Takashi Hashihayata, Jun-ichi Yamaguchi, Kenji Hashimoto & Shigeyuki Chaki. (2017)
Antidepressant Potential of (
R
)-Ketamine in Rodent Models: Comparison with (
S
)-Ketamine
. Journal of Pharmacology and Experimental Therapeutics 361:1, pages 9-16.
Crossref
Crossref
Louise K. Refsgaard, Darryl S. Pickering & Jesper T. Andreasen. (2017) Investigation of antidepressant-like and anxiolytic-like actions and cognitive and motor side effects of four N-methyl-d-aspartate receptor antagonists in mice. Behavioural Pharmacology 28:1, pages 37-47.
Crossref
Crossref
D M Rotroff, D G Corum, A Motsinger-Reif, O Fiehn, N Bottrel, W C Drevets, J Singh, G Salvadore & R Kaddurah-Daouk. (2016) Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants. Translational Psychiatry 6:9, pages e894-e894.
Crossref
Crossref
Ying Xu, Maree Hackett, Gregory Carter, Colleen Loo, Verònica Gálvez, Nick Glozier, Paul Glue, Kyle Lapidus, Alexander McGirr, Andrew A. Somogyi, Philip B. Mitchell & Anthony Rodgers. (2016) Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: a Systematic Review and Meta-Analysis. International Journal of Neuropsychopharmacology 19:4, pages pyv124.
Crossref
Crossref
Bai Li, Yangyang Hou, Ming Zhu, Hongkun Bao, Jun Nie, Grace Y. Zhang, Liping Shan, Yao Yao, Kai Du, Hongju Yang, Meizhang Li, Bingrong Zheng, Xiufeng Xu, Chunjie Xiao & Jing Du. (2016) 3’-Deoxyadenosine (Cordycepin) Produces a Rapid and Robust Antidepressant Effect via Enhancing Prefrontal AMPA Receptor Signaling Pathway. International Journal of Neuropsychopharmacology 19:4, pages pyv112.
Crossref
Crossref
Keith G. Rasmussen. (2016) Has psychiatry tamed the “ketamine tiger?” Considerations on its use for depression and anxiety. Progress in Neuro-Psychopharmacology and Biological Psychiatry 64, pages 218-224.
Crossref
Crossref
Lynnette A. Averill, James W. Murrough & Chadi G. Abdallah. 2016. Ketamine for Treatment-Resistant Depression. Ketamine for Treatment-Resistant Depression
99
121
.
Elizabeth Wolf Fourcade & Kyle A. B. Lapidus. 2016. Ketamine for Treatment-Resistant Depression. Ketamine for Treatment-Resistant Depression
13
29
.
Lee C. Chang, Suman Rajagopalan & Sanjay J. Mathew. 2016. Ketamine for Treatment-Resistant Depression. Ketamine for Treatment-Resistant Depression
1
12
.
Mitsumasa Kurita, Aintzane García-Bea & Javier González-Maeso. 2016. The Medical Basis of Psychiatry. The Medical Basis of Psychiatry
601
654
.
R. Rajkumar, J. Fam, E.Y.M. Yeo & G.S. Dawe. (2015) Ketamine and suicidal ideation in depression: Jumping the gun?. Pharmacological Research 99, pages 23-35.
Crossref
Crossref
Ruin Moaddel, Mitesh Sanghvi, Katina Sourou Sylvestre Dossou, Anuradha Ramamoorthy, Carol Green, James Bupp, Robert Swezey, Kathleen O'Loughlin & Irving W. Wainer. (2015) The distribution and clearance of (2S,6S)‐hydroxynorketamine, an active ketamine metabolite, in Wistar rats. Pharmacology Research & Perspectives 3:4.
Crossref
Crossref
E. Drewniany, J. Han, C. Hancock, R. L. Jones, J. Lim, N. Nemat Gorgani, J. K. SperryIIIIII, H. J. Yu & R. B. Raffa. (2015) Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression. Journal of Clinical Pharmacy and Therapeutics 40:2, pages 125-130.
Crossref
Crossref
Arpan Dutta, Shane McKie & J.F. William Deakin. (2015) Ketamine and other potential glutamate antidepressants. Psychiatry Research 225:1-2, pages 1-13.
Crossref
Crossref
Mehdi Ghasemi, Cristy Phillips, Ludwig Trillo, Zurine De Miguel, Devsmita Das & Ahmad Salehi. (2014) The role of NMDA receptors in the pathophysiology and treatment of mood disorders. Neuroscience & Biobehavioral Reviews 47, pages 336-358.
Crossref
Crossref
Marie Naughton, Gerard Clarke, Olivia F. O′Leary, John F. Cryan & Timothy G. Dinan. (2014) A review of ketamine in affective disorders: Current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. Journal of Affective Disorders 156, pages 24-35.
Crossref
Crossref
Ji-chun Zhang, Su-xia Li & Kenji Hashimoto. (2014) R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacology Biochemistry and Behavior 116, pages 137-141.
Crossref
Crossref
Felix Segmiller, Tobias Rüther, Andrea Linhardt, Frank Padberg, Michael Berger, Oliver Pogarell, Hans-Jürgen Möller, Christina Kohler & Cornelius Schüle. (2013) Repeated S-ketamine Infusions in Therapy Resistant Depression: A Case Series. The Journal of Clinical Pharmacology 53:9, pages 996-998.
Crossref
Crossref
Natalie Katalinic, Rosalyn Lai, Andrew Somogyi, Philip B Mitchell, Paul Glue & Colleen K Loo. (2013) Ketamine as a new treatment for depression: A review of its efficacy and adverse effects. Australian & New Zealand Journal of Psychiatry 47:8, pages 710-727.
Crossref
Crossref
F. Segmiller, D. Frisse, D. Eser, H.-J. Möller, T. Rüther & C. Schüle. (2012) Ketamin zur Behandlung der therapieresistenten DepressionKetamine for treatment of therapy-resistant depression. Der Nervenarzt 84:7, pages 854-855.
Crossref
Crossref
Gerhard Köpf. (2013) Charles Bovary. Landarzt. NeuroTransmitter 24:6, pages 72-78.
Crossref
Crossref
Dominique Piber, Francesca Regen & Franziska van Hall. (2013) Depression: Alternative bei Therapieresistenz. NeuroTransmitter 24:6, pages 56-60.
Crossref
Crossref
. 2013. Clinical Handbook for the Management of Mood Disorders. Clinical Handbook for the Management of Mood Disorders
311
357
.
Keith G Rasmussen, Timothy W Lineberry, Christine W Galardy, Simon Kung, Maria I Lapid, Brian A Palmer, Matthew J Ritter, Kathryn M Schak, Christopher L Sola, Allison J Hanson & Mark A Frye. (2013) Serial infusions of low-dose ketamine for major depression. Journal of Psychopharmacology 27:5, pages 444-450.
Crossref
Crossref
Jan van Amsterdam, David NuttWim van den Brink. (2013) Generic legislation of new psychoactive drugs. Journal of Psychopharmacology 27:3, pages 317-324.
Crossref
Crossref
Kyle A.B. Lapidus & Sanjay J. Mathew. 2013. Clinical Handbook for the Management of Mood Disorders. Clinical Handbook for the Management of Mood Disorders
345
357
.
Marije aan het Rot, Carlos A. ZarateJr.Jr., Dennis S. Charney & Sanjay J. Mathew. (2012) Ketamine for Depression: Where Do We Go from Here?. Biological Psychiatry 72:7, pages 537-547.
Crossref
Crossref
Dan J SteinHarish KalraOlivia DeanSeetal DoddMichael Berk. 2012. Antidepressants and Major Depressive Disorder. Antidepressants and Major Depressive Disorder
94
107
.
Blynn G. Bunney & William E. Bunney. (2011) Rapid-acting antidepressant strategies: mechanisms of action. The International Journal of Neuropsychopharmacology 15:05, pages 695-713.
Crossref
Crossref
Matthew J. Robson, Meenal Elliott, Michael J. Seminerio & Rae R. Matsumoto. (2012) Evaluation of sigma (σ) receptors in the antidepressant-like effects of ketamine in vitro and in vivo. European Neuropsychopharmacology 22:4, pages 308-317.
Crossref
Crossref
Sanjay J. Mathew, Asim Shah, Kyle Lapidus, Crystal Clark, Noor Jarun, Britta Ostermeyer & James W. Murrough. (2012) Ketamine for Treatment-Resistant Unipolar Depression. CNS Drugs 26:3, pages 189-204.
Crossref
Crossref
Jordan R Covvey, Alexis Noble Crawford & Denise K Lowe. (2012) Intravenous Ketamine for Treatment-Resistant Major Depressive Disorder. Annals of Pharmacotherapy 46:1, pages 117-123.
Crossref
Crossref
Thomas C. Baghai, Pierre Blier, David S. Baldwin, Michael Bauer, Guy M. Goodwin, Kostas N. Fountoulakis, Siegfried Kasper, Brian E. Leonard, Ulrik F. Malt, Dan Stein, Marcio Versiani & Hans-Jürgen Möller. (2011) General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry. European Archives of Psychiatry and Clinical Neuroscience 261:S3, pages 207-245.
Crossref
Crossref
Kenji Hashimoto. (2011) The role of glutamate on the action of antidepressants. Progress in Neuro-Psychopharmacology and Biological Psychiatry 35:7, pages 1558-1568.
Crossref
Crossref
Colleen Loo, Brett Simpson & Ross MacPherson. (2010) Augmentation Strategies in Electroconvulsive Therapy. The Journal of ECT 26:3, pages 202-207.
Crossref
Crossref
. (2010) Current World Literature. Current Opinion in Anaesthesiology 23:4, pages 532-538.
Crossref
Crossref
T.SSathyanarayana Rao & Chittaranjan Andrade. (2010) Innovative approaches to treatment - refractory depression: The ketamine story. Indian Journal of Psychiatry 52:2, pages 97.
Crossref
Crossref
Robert H. Howland. (2009) Clinical Implications of Chirality and Stereochemistry in Psychopharmacology. Journal of Psychosocial Nursing and Mental Health Services 47:8, pages 17-21.
Crossref
Crossref